{"id":"W4295837529","doi":"10.1016/j.annonc.2022.08.070","title":"LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":20,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Calgary","funders":"","keywords":"Medicine; Clinical endpoint; Ipilimumab; Internal medicine; Nivolumab; Population; Cabozantinib; Placebo; Randomized controlled trial; Progression-free survival; Intention-to-treat analysis; Oncology; Phases of clinical research; Gastroenterology; Urology; Renal cell carcinoma; Cancer; Clinical trial; Chemotherapy; Immunotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001058488,0.001363368,0.002002844,0.0004514033,0.0005105768,0.001475356,0.001094429,0.001116038,0.005141569],"category_scores_gemma":[0.0005870448,0.0006024807,0.001649968,0.0004103105,0.0008186608,0.0007337165,0.0003669203,0.0036796,0.001936229],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001610708,"about_ca_system_score_gemma":0.002030421,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003813637,"about_ca_topic_score_gemma":0.009639864,"domain_scores_codex":[0.9997606,0.00008365588,0.00001075973,0.00004816513,0.00002276219,0.00007415155],"domain_scores_gemma":[0.999541,0.0000457989,0.00006694307,0.00003088806,0.00003493866,0.0002803771],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7603891,0.03789135,0.005744588,0.001292171,0.002733893,0.0002898087,0.0003594806,0.003221704,0.04087057,0.0007035584,0.01315576,0.133348],"study_design_scores_gemma":[0.7230043,0.2455016,0.01254839,0.0001118713,0.001240364,0.0004686039,0.0001457928,0.002222024,0.004104442,0.0003866117,0.01021194,0.00005408079],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9833276,0.005210431,0.0005831444,0.0009531967,0.0004517551,0.001470741,0.002395243,0.0003728439,0.005235151],"genre_scores_gemma":[0.9795559,0.00344986,0.0021575,0.001302029,0.000215717,0.001702869,0.00483636,0.00008198728,0.006697845],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005141569,"threshold_uncertainty_score":0.01720023,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0515036698503485,"score_gpt":0.3865891785426204,"score_spread":0.3350855086922719,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}